CoChat

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Open access
Graham, Carl, Seow, Jeffrey, Huettner, Isabella, Khan, Hataf, Kouphou, Neophytos, Acors, Sam, Winstone, Helena, Pickering, Suzanne, Galao, Rui Pedro, Dupont, Liane, Lista, Maria Jose, Jimenez-Guardeño, Jose M., Laing, Adam G., Wu, Yin, Joseph, Magdalene, Muir, Luke, van Gils, Marit J., Ng, Weng M., Duyvesteyn, Helen M.E., Zhao, Yuguang, Bowden, Thomas A., Shankar-Hari, Manu, Rosa, Annachiara, Cherepanov, Peter, McCoy, Laura E., Hayday, Adrian C., Neil, Stuart J.D., Malim, Michael H., Doores, Katie J. · 2021 · Immunity
Cited by 152

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.03.023

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 152

Metadata

Authors
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Dupont, L., Lista, M. J., Jimenez-Guardeño, J. M., Laing, A. G., Wu, Y., Joseph, M., Muir, L., van Gils, M. J., Ng, W. M., Duyvesteyn, H. M. E., Zhao, Y., Bowden, T. A., Shankar-Hari, M., Rosa, A., Cherepanov, P., McCoy, L. E., Hayday, A. C., Neil, S. J. D., Malim, M. H., & Doores, K. J.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-06
Volume
54
Issue
6
Pages
1276-1289.e6
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3144506870
Cited by
152
References
47
FWCI
9.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. https://app.cochat.ai/papers/10.1016/j.immuni.2021.03.023
The paper
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Dupont, L., Lista, M. J., Jimenez-Guardeño, J. M., Laing, A. G., Wu, Y., Joseph, M., Muir, L., van Gils, M. J., Ng, W. M., Duyvesteyn, H. M. E., . . . Doores, K. J. (2021). Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity. https://doi.org/10.1016/j.immuni.2021.03.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.